Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
Key Highlights
- ➤$3.0 billion USD senior-note offering priced across four maturities through 2036
- ➤€4.25 billion Euro Notes priced across maturities through 2046
- ➤Proceeds intended to finance Boston Scientific’s Penumbra acquisition and related expenses
- ➤Offerings expected to close December 1, 2026, subject to customary conditions
- ➤Penumbra deal failure triggers 101% special mandatory redemption, excluding Floating Rate Notes
Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes PR Newswire
MARLBOROUGH, Mass., Nov. 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal amount of U.S. dollar-denominated notes (the "USD Offering"), consisting of $1,000,000,000 aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the "USD Notes").
Get started
Create a free account to read the full story.
